- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Pulmonary arterial hypertension (PAH)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1695KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 871KB)
Selexipag – July 2020
Selexipag: Tablet 200 microgram, Tablet 400 microgram, Tablet 600 microgram, Tablet 800 microgram, Tablet 1 mg, Tablet 1.2 mg, Tablet 1.4 mg, Tablet 1.6 mg; Uptravi®
Last updated
30 October 2020